Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $6.10.

APLT has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Applied Therapeutics to a "sell" rating in a research note on Thursday, May 22nd. Royal Bank of Canada reiterated a "sector perform" rating and issued a $1.50 price objective on shares of Applied Therapeutics in a report on Wednesday, May 14th.

Institutional Trading of Applied Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of Applied Therapeutics in the 1st quarter valued at about $280,000. Alyeska Investment Group L.P. lifted its stake in Applied Therapeutics by 14.8% in the first quarter. Alyeska Investment Group L.P. now owns 3,107,497 shares of the company's stock valued at $1,519,000 after buying an additional 400,000 shares during the last quarter. Propel Bio Management LLC boosted its holdings in shares of Applied Therapeutics by 17.4% in the first quarter. Propel Bio Management LLC now owns 11,285,420 shares of the company's stock valued at $5,517,000 after acquiring an additional 1,670,000 shares during the period. CreativeOne Wealth LLC grew its position in shares of Applied Therapeutics by 132.2% during the first quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company's stock worth $25,000 after acquiring an additional 28,701 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. increased its holdings in shares of Applied Therapeutics by 91.5% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 10,380,590 shares of the company's stock valued at $5,076,000 after acquiring an additional 4,959,670 shares during the period. Institutional investors and hedge funds own 98.31% of the company's stock.

Applied Therapeutics Price Performance

APLT stock opened at $0.37 on Friday. The business's 50-day moving average is $0.39 and its two-hundred day moving average is $0.98. The firm has a market capitalization of $52.27 million, a P/E ratio of -0.23 and a beta of 1.86. Applied Therapeutics has a 1 year low of $0.30 and a 1 year high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last issued its quarterly earnings results on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.61 million. On average, analysts expect that Applied Therapeutics will post -0.65 EPS for the current year.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.